The Case for Sunshine (with Rowan Jacobsen)

Episode Summary

Executive Summary: Russ Roberts and Rowan Jacobson discuss Jacobson’s book arguing that sunlight’s benefits have been underestimated. While sunburn and some skin cancer risks are real, the transcript emphasizes evidence that moderate sun exposure may improve cardiovascular health, vitamin D status, mood, and possibly other outcomes. The conversation stresses trade-offs, overdiagnosis in skin cancer, and the importance of moderation rather than total avoidance.

Main Topics: Reassessing sunlight as a health factor (Priority: 5/5): Jacobson argues the public-health narrative has overfocused on sunlight as a danger and underweighted its potential benefits, especially with moderate exposure. Historical swing from heliotherapy to sun avoidance (Priority: 4/5): The discussion traces how early 20th-century medicine embraced sunlight for tuberculosis and rickets, then reversed as skin-cancer concerns rose. Skin cancer trends, diagnosis, and overdiagnosis (Priority: 5/5): Roberts and Jacobson distinguish melanoma from common non-melanoma skin cancers, and note that rising incidence partly reflects more screening and changing diagnostic thresholds. Sunscreen, SPF, and formulation limits (Priority: 4/5): They explain how early sunscreens mainly blocked UVB, not UVA, and why this may have limited their protective impact. Modern broad-spectrum products are better. Vitamin D: observational promise vs trial disappointment (Priority: 5/5): Vitamin D levels correlate with many good health outcomes, but supplementation trials largely fail to reproduce benefits, suggesting sunlight may help through other pathways or that vitamin D is a proxy. Nitric oxide, blood pressure, and trade-offs (Priority: 5/5): A key mechanism discussed is sunlight-induced nitric oxide, which may lower blood pressure and produce large population-level cardiovascular benefits that could outweigh skin-cancer harms. Practical advice: moderation, skin type, and context (Priority: 4/5): The conversation concludes with individualized guidance: avoid burns, do not seek zero sun, and adjust exposure to skin tone, age, and location.

Key Arguments: Sun exposure has real risks, especially sunburn and melanoma, but the health picture is broader than cancer risk alone. A large share of the rise in diagnosed skin cancer likely reflects increased screening, dermatologist supply, and broader definitions rather than only more dangerous sunlight exposure. Melanoma incidence has risen while mortality has remained flat, a pattern consistent with substantial overdiagnosis. Older sunscreens often blocked UVB but not UVA, so they may have reduced burns without fully preventing cancer-causing exposure. Vitamin D deficiency correlates with many diseases, but randomized supplementation trials generally fail to improve outcomes, suggesting the blood marker may not be the causal agent. Sunlight may confer health benefits via nitric oxide production, including lower blood pressure, which could materially reduce cardiovascular deaths. The best policy is not total avoidance but careful moderation, with much stricter caution for very fair-skinned people and those prone to burning.

Data Points: Publication date of episode: May 18, 2026 - Opening of the conversation with Rowan Jacobson about In Defense of Sunlight. Share of skin cancer cases: About 98% - Non-melanoma skin cancers (squamous cell and basal cell carcinoma) account for nearly all cases. Melanoma share of skin cancer cases: About 2% - Melanoma is the smaller but most dangerous category of skin cancer. U.S. skin cancer deaths annually: About 10,000 - Used to compare skin cancer mortality with far larger causes of death. UK Biobank sample size: About 420,000 people - Weller’s preprint used this cohort to analyze sun exposure and mortality. UK Biobank deaths in cohort: About 45,000 - Total deaths observed over roughly 20 years in the cohort. Melanoma deaths in cohort: 440 - Deaths from melanoma among 420,000 participants. Deaths from other skin cancers in cohort: 60 - Deaths from non-melanoma skin cancers among 420,000 participants. Relative risk from high sun exposure: About 20% more likely to die of melanoma - High sun exposure was associated with a modest increase in melanoma mortality. Estimated trade-off ratio: About 75:1 - For every extra melanoma death, sunlight exposure was associated with roughly 75 fewer deaths from other diseases in the Weller analysis. Blood pressure effect: Lowered by about 5–6 points - Sunlight exposure in Weller’s nitric-oxide experiments lowered blood pressure in volunteers. Sunlight duration in experiments: 20–25 minutes - Approximate amount of summer sunlight used in the nitric-oxide study. Vitamin D production at age 70: About half of the rate in the 30s - Age reduces the skin’s ability to synthesize vitamin D from sunlight. Live-work shift in workforce: Farming fell from 40% to 3% - Illustrates the long-term move from outdoor to indoor work over the 20th century. Catalytic historical mortality: One out of every four deaths in Europe - Tuberculosis burden in the late 1800s helped drive heliotherapy.

Pivotal Quotes: "The sun is not bad for you. In fact, it's good for you." — Russ Roberts: Roberts offers a concise summary of Jacobson’s thesis early in the conversation. "It's kind of like if orthopedists started telling people, stop exercising, because when you exercise, your risk of knee injuries goes way up." — Rowan Jacobson: Analogy used to explain how focusing only on sun-related harm misses broader health benefits. "Moderation, once again, is going to end up being the best policy here." — Rowan Jacobson: Jacobson’s practical bottom line on how listeners should think about sunlight.

Implications: Listeners should reject both extremes: no sun and nonstop tanning. The conversation suggests individualized, moderate exposure may improve health, while sunscreen technology, age, and skin type should shape decisions. More nuanced public-health guidance and better U.S. sunscreen options may follow.